To evaluate and compare the efficacy of 18F-FDG PET taken in hyperglycemic state, 18F-FDG PET taken in NPO state, and C-11 acetate PET in detecting and grading brain tumor

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0004466

Enrollment

Registered

2019-11-25

Start date

2019-06-24

Completion date

Unknown

Last updated

2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Others : For fasting scans, all patients fasted for at least 6 hours, following which blood glucose concentration was confirmed to be less than 140 mg/dL before the injection of 18F-FDG. For glucose l

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Adult men and women over the age of 20 2. First diagnosed primary brain tumor patient 3. Patients scheduled to undergo cancer resection as their primary treatment

Exclusion criteria

Exclusion criteria: 1. Patients who have undergone chemotherapy or radiation therapy for pretreatment 2. A pregnant patient 3. Patients or guardians who do not understand or do not accept consent 4. Uncontrolled diabetes

Design outcomes

Primary

Measure	Time frame
The SUV results of the preoperative hyperglycemic F-18 FDG PET are compared with the conventional imaging technique (NPO F-18 FDG PET, C-11 Acetate PET).	—

Secondary

Measure	Time frame
SUV results of preoperative hyperglycemic F-18 FDG PET are compared with conventional imaging techniques (NPO F-18 FDG PET, C-11 Acetate PET) to compare the predictive outcome of patients.	—

Countries

Korea, Republic of

Contacts

Public ContactDongwoo Kim

Yonsei University Health System, Severance Hospital

kdwoo@yuhs.ac+82-2-2228-4852

Outcome results